Company profile: Exact Imaging
1.1 - Company Overview
Company description
- Provider of 29 MHz micro-ultrasound imaging for real-time targeted prostate biopsies via the ExactVu system, offering high-resolution visualization and enhancements like ExactVu Micro Doppler. Solutions include PRI-MUS protocol for prostate cancer risk assessment, FusionVu for MRI-ultrasound alignment and targeting, and Cognitive Assist for cognitive fusion displaying MRI-identified lesions in real time.
Products and services
- ExactVu™: The first 29 MHz micro-ultrasound system that delivers unmatched resolution imaging for real-time targeted prostate biopsies
- FusionVu™: A real-time system that imports, aligns, and targets MRI-identified lesions using micro-ultrasound imaging, unifying MRI data with live ultrasound for accurate lesion targeting
- PRI-MUS™: A protocol-based system that identifies prostate cancer risk using micro-ultrasound, guiding targeted biopsies based on sonographic features
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Exact Imaging
Progenics Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics for cancer and related conditions, developing PSMA-targeted radioligand therapies (PNT2002, LNTH-1095), diagnostic imaging agents (LNTH-1404), and antibodies (PSMA-TAC), plus a somatostatin receptor-targeted radioligand therapy (PNT2003) for neuroendocrine tumors, alongside pipeline candidates such as PSMA ADC and LNTH-1558 in various clinical and preclinical stages.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Progenics Pharmaceuticals company profile →
Kura Oncology
HQ: United States
Website
- Description: Provider of precision medicines for solid tumors and blood cancers, advancing investigational therapies including ziftomenib for AML with specific mutations, tipifarnib for HRAS-mutant head and neck squamous cell carcinoma and other cancers, and KO-2806, a next-generation FTI for advanced solid tumors; also conducts clinical trials and offers expanded access programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kura Oncology company profile →
Codiak BioSciences
HQ: United States
Website
- Description: Provider of pioneering development of exosome-based therapeutics as a clinical-stage biopharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Codiak BioSciences company profile →
IDRx
HQ: United States
Website
- Description: Provider of oncology-based precision therapies for gastrointestinal stromal tumors (GIST). The clinical-stage biopharma designs precision combination medicines with engineered drug combinations to stop key tumor escape mechanisms and prolong response. Pipeline includes IDRX-42, a Phase 1 small-molecule tyrosine kinase inhibitor targeting genetic drivers and resistance mutations in GIST, and IDRX-73 targeting a key drug resistance mutation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IDRx company profile →
Secretome Therapeutics
HQ: United States
Website
- Description: Provider of neonatal mesenchymal stem cell-based therapeutics and secretome-based regenerative therapies for heart failure and neurodegenerative and dermatological diseases, including STM-01 for adult and pediatric heart failure and NEO2001 for chronic ischemic heart failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Secretome Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Exact Imaging
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Exact Imaging
2.2 - Growth funds investing in similar companies to Exact Imaging
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Exact Imaging
4.2 - Public trading comparable groups for Exact Imaging
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →